510(k) · Neurology

REMI-AI Rapid Detection Module (REMI-AI RDM)

by Epitel, Inc

REMI-AI Rapid Detection Module (REMI-AI RDM) is an AI-enabled medical device from Epitel, Inc that the U.S. FDA cleared through 510(k) K240408 on October 17, 2024. Its lead review panel is Neurology and its primary product code is OMB (Automatic Event Detection Software For Full-Montage Electroencephalograph).

See also FDA-cleared AI neurology devices in 2024, all FDA AI clearances in 2024, top neurology AI devices.

Key facts

Submission numberK240408
Pathway510(k)
Date of final decision
Company (FDA list)Epitel, Inc
Lead review panelNeurology
Primary product codeOMB — Automatic Event Detection Software For Full-Montage Electroencephalograph
Applicant (openFDA)Epitel, Inc.
Applicant locationSalt Lake City, UT, US
Device classClass 2
Regulation number21 CFR 882.1400
Decision codeSESE
Submission typeTraditional

Source: FDA AI-Enabled Medical Devices list and openFDA.

What this means

A 510(k) is a premarket submission showing the device is substantially equivalent to a legally marketed predicate device. A cleared 510(k) means FDA agreed with that equivalence. REMI-AI Rapid Detection Module (REMI-AI RDM) went through this pathway (K240408).

openFDA lists it as a Class 2 device under 21 CFR 882.1400. Class II devices are moderate risk and are subject to general and special controls.

Product code OMB covers 8 devices on the FDA AI list. By decision date, this device is #6 of 8 under that code. Epitel, Inc has 2 AI-enabled devices on the list, and the Neurology panel accounts for 73 in total.

Being on this list doesn't describe how well the device works clinically. Check the FDA record for its indications for use.

Similar devices (product code OMB)

More from Epitel, Inc